Skip to main content

The PEERLESS II Study

Completed · Not applicable · NCT06055920

Conditions: Pulmonary Embolism

At a glance

Research payments reported, 2025
$1.6M
U.S. investigators named
11
Sites paid
54
Planned or actual enrollment
1,200

About the trial

Sponsor
Inari Medical
Tested
FlowTriever System (device), Anticoagulation Agents (drug)
Dates
Started 2023-11-17; completion 2026-10-30
Results posted
Not yet

This study is a prospective, multicenter, randomized controlled trial of the FlowTriever System plus anticoagulation compared to anticoagulation alone for intermediate-risk acute PE.

From ClinicalTrials.gov, last updated 2026-11-03. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Stryker Corporation reported $1.6M in research payments for this study in 2025 (951 payments).

Products named: Flowtriever Catheter, S

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.